Dr. LeBlanc Discusses End-of-Life Care for Hematologic Malignancies

Thomas W. LeBlanc, MD
Published: Thursday, Oct 26, 2017



Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Currently, the quality outcome measures for palliative and end-of-life care focus more on end-of-life than upstream palliative care.

Outcomes for patients with hematologic malignancies appear to be worse across the board when managed by these measures compared with patients with solid tumors, says LeBlanc.
 
SELECTED
LANGUAGE


Thomas W. LeBlanc, MD, MA, medical oncologist, palliative care physician, Duke Cancer Institute, discusses end-of-life care for patients with hematologic malignancies.

Currently, the quality outcome measures for palliative and end-of-life care focus more on end-of-life than upstream palliative care.

Outcomes for patients with hematologic malignancies appear to be worse across the board when managed by these measures compared with patients with solid tumors, says LeBlanc.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Advances in™ Diagnostic Guidelines for Effective Clinical Decision - Making in the Management of Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x